Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Dexmedetomidine is a Central alpha-2 Adrenergic Agonist. The mechanism of action of dexmedetomidine is as an Adrenergic alpha2-Agonist. The physiologic effect of dexmedetomidine is by means of General Anesthesia.
Description | Dexmedetomidine is a Central alpha-2 Adrenergic Agonist. The mechanism of action of dexmedetomidine is as an Adrenergic alpha2-Agonist. The physiologic effect of dexmedetomidine is by means of General Anesthesia. |
Targets&IC50 | α2 receptor:1.08 nM(Ki ) |
In vitro | Dexmedetomidine has a relatively high ratio of α2/α1-activity (1620:1 as compared with 220:1 for clonidine) and, therefore, is considered a full agonist of the α2 receptor. This may result in more potent effects of sedation without unwanted cardiovascular effects from α1 receptor activation. The 2-h half-life of dexmedetomidine is nearly 4-fold shorter than that of clonidine, which increases the likelihood that a continuous infusion of dexmedetomidine might be useful for sedation. Dexmedetomidine also has minimum alveolar anesthetic concentration (MAC)-sparing properties, but its use as an anesthetic adjuvant has been complicated by persistent hypotension that has mandated IV fluid administration and vasopressor administration. In addition, its use in large doses is complicated by hypertension from α2 receptor-mediated vascular constriction. |
Molecular Weight | 200.285 |
Formula | C13H16N2 |
CAS No. | 113775-47-6 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 40 mg/mL (199.72 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Dexmedetomidine 113775-47-6 G蛋白偶联受体 神经科学 Adrenergic Receptor analgesia Inhibitor (S)-Medetomidine adrenoceptor inhibit (+)-Medetomidine Beta Receptor sedation anxiolysis inhibitor